Artificial Sphincters For Urinary Incontinence — Cost, Top Hospitals & Success Rates | MyMedicPlus

The artificial urinary sphincter (AUS) is a surgically implanted device designed to restore urinary continence in patients with severe intrinsic sphincter deficiency — most commonly men who have developed stress urinary incontinence following radical prostatectomy for prostate cancer, and women with refractory stress incontinence due to sphincteric weakness. The AUS AMS 800 (American Medical Systems) is the gold-standard device and has been in clinical use for over four decades, with more than 150,000 implantations performed worldwide.

The device consists of three components connected by silicone-coated tubing: a fluid-filled cuff that encircles the urethra and maintains gentle resting occlusion preventing urine leakage, a pressure-regulating balloon reservoir implanted in the retropubic space that acts as the fluid reservoir and determines the cuff pressure, and a control pump implanted in the scrotum (men) or labia (women) that the patient activates manually to transfer fluid from the cuff to the reservoir temporarily, allowing voiding. The cuff automatically re-inflates within 3–5 minutes after activation, restoring continence.

The surgical procedure is performed under general or spinal anaesthesia through perineal (men) or vaginal/abdominal (women) incisions. Precise placement of the urethral cuff at the bulbomembranous urethra in men — or around the bladder neck in women — requires meticulous dissection to achieve optimal function without urethral erosion. The device is deactivated post-operatively and activated 4–6 weeks later once tissue healing around the cuff is complete, at which point patients are instructed in pump manipulation technique.

The primary indication is post-prostatectomy stress urinary incontinence (SUI) in men — affecting approximately 5–10% of patients following radical prostatectomy for prostate cancer who experience persistent moderate-to-severe leakage (more than 2–3 pads per day) beyond 12 months despite pelvic floor physiotherapy. Sphincteric weakness following radiotherapy to the prostate or bladder, transurethral resection of the prostate (TURP), or other urological procedures is also amenable to AUS implantation.

In women, AUS implantation is reserved for severe intrinsic sphincter deficiency (ISD) — a condition where the urethral sphincter has intrinsically poor closure function — after mid-urethral sling procedures (TVT, TOT) have failed or are contraindicated. Women with post-radiotherapy incontinence following treatment for gynaecological or rectal cancers who have severe sphincter weakness represent another important population. Neurogenic bladder dysfunction causing sphincter incompetence in patients with spinal cord injury or myelomeningocele may also benefit from AUS implantation as part of a comprehensive urological reconstruction programme.

Ideal candidates are men with persistent moderate-to-severe post-prostatectomy stress urinary incontinence of more than 12 months duration who have not responded to pelvic floor muscle training (Kegel exercises), are willing and physically able to manually operate the scrotal pump, and have a normal cystoscopic appearance of the urethra without stricture, radiation damage, or active infection. Urodynamic studies confirming intrinsic sphincter deficiency with a low Valsalva leak point pressure and preserved bladder capacity are recommended before implantation.

Contraindications include urethral stricture disease at the planned cuff site requiring treatment before implantation, active urinary tract infection or pelvic infection, an unstable overactive bladder that would not be controlled by the device, significant radiation necrosis of the urethra, insufficient manual dexterity to operate the pump (particularly in elderly patients), and poor surgical fitness from severe cardiovascular or pulmonary disease. Previous AUS explantation for erosion or infection significantly increases the risk of complications with reimplantation, and careful discussion of risks versus benefits is essential.

The AMS 800 remains the overwhelmingly preferred AUS device globally. In men, the urethral cuff is placed at the bulbomembranous urethra via a perineal incision, with the pressure-regulating balloon positioned in the retropubic space through an inguinal incision, and the control pump placed in the ipsilateral hemiscrotum. Cuff size (ranging from 3.5 to 11 cm in circumference) is selected intraoperatively by direct urethral measurement. The standard pressure-regulating balloon maintains cuff pressure of 61–70 cmH₂O; higher-pressure balloons (71–80 cmH₂O) are used in patients with prior radiation treatment where higher occlusive pressure may be needed.

In women and some men with prior pelvic surgery, bladder neck cuff placement through a low abdominal approach is preferred. Tandem cuff implantation (two cuffs in series) is used in revision cases or severe continence requirements. As an alternative to AUS in mild-to-moderate post-prostatectomy incontinence, male urethral slings (AdVance sling, Virtue sling) offer a less invasive implanted option, though their efficacy is significantly lower for severe incontinence and they are unsuitable for patients who have received prior radiation.

Selecting the most appropriate Artificial Sphincters For Urinary Incontinence approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

The AUS AMS 800 achieves social continence (0–1 pad per day) in 70–85% of men with post-prostatectomy incontinence at 5-year follow-up, with complete dryness in approximately 40–60%. Patient satisfaction rates exceed 80–90% in large multicentre series. Quality of life improvements are substantial and sustained, with statistically significant improvements in urinary symptom scores, sexual function (by eliminating pad use), and psychological wellbeing.

Long-term device survival is good: approximately 70–75% of implants remain functional without revision at 10 years. Mechanical failure rates with the modern AMS 800 design are approximately 1–3% per year after the initial period. Revision surgery — for cuff erosion, infection, or mechanical failure — is required in approximately 20–30% of patients over 10 years but typically restores continence to pre-revision levels when performed at experienced centres. The AUS is the most effective surgical treatment for severe post-prostatectomy urinary incontinence, consistently outperforming alternative surgical approaches.

Urethral erosion — where the cuff erodes through the urethral wall into the lumen — is the most serious device-specific complication, occurring in 4–8% of patients, typically within the first 3 years. Risk factors include prior radiotherapy (doubling erosion risk), urethral stricture disease, and overly aggressive post-operative pump activation. Erosion requires immediate device explantation and urethral repair, with reimplantation possible after 3–6 months of urethral healing.

Device infection occurs in 1–3% of cases and is more common in diabetic patients and those with prior pelvic infection; infected devices require complete explantation and systemic antibiotic therapy. Mechanical failure of tubing, kinking, or pump malfunction necessitates surgical revision. Urethral atrophy over time may reduce cuff effectiveness, requiring downsizing of the cuff to restore occlusive pressure. Scrotal haematoma and wound complications occur in 3–5% of cases. Patients must never allow urethral instrumentation (catheterisation, cystoscopy) without first deactivating the AUS to prevent iatrogenic urethral erosion.

After AUS implantation, the device is left in a deactivated position (cuff deflated, no continence) for 4–6 weeks to allow fibrosis and tissue ingrowth around the cuff, reducing the risk of erosion. During this period, patients wear pads as they did pre-operatively. At the 4–6 week appointment, the urologist activates the device and demonstrates pump operation technique, ensuring the patient can reliably cycle the device. A continence assessment is performed at 3 months.

Long-term follow-up includes annual or biannual urology review to assess device function, check for early erosion signs (increasing incontinence, perineal pain, haematuria, or urethral bleeding), and monitor for urethral atrophy. Patients are educated to deactivate the device before any urological procedure and to attend immediately for haematuria, pain, or sudden deterioration in continence. Pelvic floor physiotherapy is continued post-implantation to optimise bladder function complementary to sphincter restoration.

Artificial urinary sphincter implantation in the United States costs between USD 25,000 and USD 50,000 including device, surgeon, anaesthesia, and hospital fees. The AMS 800 device alone costs approximately USD 8,000–12,000. Insurance coverage through Medicare and private insurers is generally available for documented post-prostatectomy incontinence failing conservative management, though pre-authorisation requirements apply.

Medical tourists can access AUS implantation at centres in India for approximately USD 6,000–10,000, in Thailand USD 9,000–15,000, in Turkey USD 8,000–13,000, and in Germany USD 18,000–28,000 — achieving savings of 40–70% compared to US costs. Patients travelling internationally for this procedure should confirm that the centre uses the AMS 800 device and that the urological surgeon has experience with at least 50–100 AUS implantations, as surgical technique is strongly correlated with outcomes and complication rates. A minimum 2-week local stay is recommended for device deactivation management and initial wound healing.

For mild-to-moderate post-prostatectomy stress incontinence (1–2 pads per day), male urethral slings — particularly the retro-urethral transobturator AdVance sling — provide a less invasive surgical option with good outcomes (50–70% social continence rate) without an externally operated device. Slings are preferred for mildly incontinent patients who prefer a simpler device without manual pump operation. However, slings are not suitable for severe incontinence or post-radiation patients.

Conservative measures including intensive supervised pelvic floor muscle training, bladder training, and lifestyle modification (fluid management, weight loss, caffeine reduction) should always precede surgical intervention. Pharmacological options — duloxetine (a serotonin-noradrenaline reuptake inhibitor) — provides modest benefit for stress incontinence but is off-label in many countries for this indication and carries side effects including nausea. Bulking agent injections (carbon-coated beads, PTFE, collagen) into the urethral submucosa are minimally invasive outpatient procedures but provide only temporary benefit (12–18 months) and are not suitable for severe sphincter weakness.